Video

The effects of corneal cross linking on preventing and treating progressive keratoconus

Author(s):

David Hutton
Conferences|ASCRS

Philip Dockery, MD, MPH, discusses his paper "Corneal cross linking for progressive keratoconus, a retrospective analysis of 515 consecutive eyes," with Ophthalmology Times' David Hutton.

Related Videos
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
Related Content
OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain
March 31st 2025

OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Alcon acquires majority interest in Aurion Biotech
March 27th 2025

Alcon acquires majority interest in Aurion Biotech

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

(Image credit: AdobeStock/Atif)
March 21st 2025

Staying the course in shifting winds

Stem cell-based CALEC therapy achieves 90% corneal surface restoration in clinical trial
March 20th 2025

Stem cell-based CALEC therapy achieves 90% corneal surface restoration in clinical trial

© 2025 MJH Life Sciences

All rights reserved.